Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GlaxoSmithKline considering business break-up following investor pressure - FT report

The newspaper said GSK’s chairman Philip Hampton has been in discussions with the FTSE 100-listed group’s biggest shareholders about the creation of a standalone pharma and vaccines company in the medium term
GSK boss Emma Walmsley
GSK is expected to outline its new approach for the division in the coming week when it reports second-quarter results

GlaxoSmithKline plc (LON:GSK) is considering breaking-up its businesses, according to a report in the Financial Times at the weekend, following investor pressure for the blue-chip drug maker to spin-off its consumer division.

The newspaper said GSK’s chairman Philip Hampton has been in discussions with the FTSE 100-listed group’s biggest shareholders about the creation of a standalone pharma and vaccines company in the medium term. The move could happen within two or three years, the report added.

READ: Bidding war brewing for GSK’s Indian Horlicks division, with Coca-Cola, Nestle and Kraft all reportedly interested

One of the company’s top ten shareholders, whom the FT did not name, acknowledged having conversations with the GSK chairman, adding that shareholders “don’t quite believe in the company.”

A GSK spokesman said the group’s priority is to improve the performance of its pharmaceutical business, especially research and development, reports added.

The company is expected to outline its new approach for the division in the coming week when it reports second-quarter results on Wednesday.

Last year, GSK’s chief executive Emma Walmsley announced a wide-ranging overhaul designed to narrow the focus of drug research and improve returns in the core pharmaceuticals business.

In April, GSK said it was divesting its rare disease gene therapy drugs to private biotech company Orchard Therapeutics.

UBS cautions on dividend cover

In a note to clients regarding the FT report, analysts at UBS commented: “Consumer accounts for c20% of GSK group EBIT and, whilst it is the slower growing part of the business, it tends not to be attributed a consumer-like multiple (in general Consumer assets within pharma companies do not get consumer-like multiples)."

They added: “On paper hence a break-up would seem to make sense, but we caution that the dividend cover as well as the current repositioning of GSK would not allow for this for a few years to come.”

UBS repeated a ‘buy’ rating and 1,600p price target on GSK. In early morning trading, GSK shares were 0.4% higher at 1,555.2p.

 -- Adds analyst comment, share price --

View full GSK profile View Profile

GlaxoSmithKline plc Timeline

Related Articles

Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
bacteria
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
1530537220_Blood-Test.jpg
July 02 2018
The research and diagnostic company develops cancer-detecting blood tests

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use